Alcyone Therapeutics
David Johnson has extensive experience in the quality assurance field, having held senior leadership roles in reputable companies such as Alcyone Therapeutics Inc., OmniGuide, and Intrinsic Therapeutics. At Alcyone Therapeutics Inc., David provides vision and leadership in driving improvements to overall quality and compliance. In previous roles, David has managed all facets of quality assurance, quality control, quality engineering, inspection, and document control activities. David's expertise includes ensuring compliance with regulatory requirements and implementing quality management systems. Prior to their roles in pharmaceutical and medical device industries, David served as a Quality Manager at GE Healthcare. David holds a degree from Bridgewater State University.
Alcyone Therapeutics
Alcyone Therapeutics is a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions. Alcyone Therapeutics is advancing a pipeline of adeno-associated virus (AAV) gene therapy programs that leverage its proprietary, next-generation CNS delivery technology platform. Alcyone Therapeutics’ lead programs target the treatment of Rett syndrome and spinal muscular atrophy with respiratory distress type 1 (SMARD1).